This chapter describes a study assessing the efficacy of a
slowly dissolving adhering oral melt currently in use for reducing dry mouth
during the day and the night in the management of gastroesophageal reflux
(GERD) while sleeping. To provide context, it is worthwhile reviewing the
historical background that led to the idea that this dry-mouth product,
XyliMelts, might alter the symptoms of GERD.
In 2006, Jeff Haley, CEO of OraCoat, Bellevue, Washington, USA, developed
a fully dissolving intraoral adhering melt that could be applied beside an oral
ulcer to reduce its pain and duration, now marketed as Renewing Melts.
Subsequently, another formulation incorporating 550 mg of xylitol, 8.5 mg
calcium carbonate to neutralize acidity of the adhesive, and a mild mint flavor
was studied to see if it could alter the sensation of dry mouth occurring
during sleep; with results indicating that it could improve perceived dry
mouth. XyliMelts was then put on the market and feedback from users indicated
that when used as directed, there seemed to be a reduction in GERD symptoms.
Given this, a randomized controlled and blinded trial was pursued to see
whether the reported anecdotes actually represented a true clinical effect.
This study confirmed that it did. Based on this research, one of the
ingredients, calcium carbonate, was increased to 300 mg in a new product to be
released under the brand name AlkaMelts.
Author(s) Details
Jeff Burgess Author(s) Details
Oral Care Research Associates, USA.
View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/212
No comments:
Post a Comment